Loading…
SELLAS Life Sciences Group, Inc. is projected to rise to $15.01 by 2027, a +11% move from its current price of $13.51. SLS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $12.67 | $13.52 | $14.43 | +0.06% |
| Jul 14 | $12.34 | $13.53 | $14.83 | +0.13% |
| Jul 15 | $12.09 | $13.54 | $15.15 | +0.20% |
| Jul 16 | $11.89 | $13.55 | $15.43 | +0.26% |
| Jul 17 | $11.72 | $13.55 | $15.68 | +0.33% |
| Jul 18 | $11.56 | $13.56 | $15.91 | +0.39% |
| Jul 19 | $11.42 | $13.57 | $16.13 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.42 | $13.57 | $16.13 | +0.46% |
| Week 2 | $10.68 | $13.63 | $17.40 | +0.91% |
| Week 3 | $10.16 | $13.70 | $18.46 | +1.37% |
| Week 4 | $9.75 | $13.76 | $19.42 | +1.84% |
| Week 5 | $9.40 | $13.82 | $20.32 | +2.30% |
| Week 6 | $9.10 | $13.88 | $21.18 | +2.77% |
| Week 7 | $8.84 | $13.95 | $22.01 | +3.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focusing on the development of novel therapeutics for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
The company maintains strategic collaborations with Merck & Co., Inc. to evaluate GPS as it is administered in combination with the PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan K K Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Galinpepimut-S and SLS009 represent the clinical focus, with GPS targeting Wilms tumor 1 antigen and tambiciclib serving as a CDK9 inhibitor, reflecting the company’s emphasis on cancer therapeutics in the U.S. market. HQ: New York, New York, anchoring a U.S. focus for its late-stage pipeline and collaborations with major research and corporate partners.
SELLAS Life Sciences Group, Inc. trades under the symbol SLS and currently sits at $13.50 per share, with a market capitalization of $2.65B. It ranks 1859 by market cap among reported equities.
The stock’s 30-day price activity spans from a low of $8.52 to a high of $21.40, illustrating notable intramonth variability within a broad range.
Technically, the picture is bullish with an RSI14 of 60. The SMA50 is $8.15 and the SMA200 is $4.48, suggesting near-term momentum above key moving averages. Support is listed at $7.15 and resistance at $15.45, framing a defined price corridor as conditions evolve.
Forecasts depict a rising multi-year path, with 2026 averaging $13.50 and 2050 averaging $169.30, accompanied by increasing ROI figures (e.g., 142.6% in 2030 and 1154.1% in 2050) and a bullish sentiment carried through many years. This indicates potential upside over the longer horizon, though actual results may differ and are not guaranteed.
A major floor 74.2% below — a decisive break under it would weaken the trend.
The nearest floor, 47.1% below — buyers have tended to step in here.
The nearest ceiling, 14.4% above — a clean break opens room to run.
A major ceiling 48.7% above — clearing it would confirm fresh momentum.
Key SLS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.49 | Buy | $13.35 | Buy |
| MA 10 | $13.83 | Sell | $12.98 | Buy |
| MA 20 | $11.11 | Buy | $11.74 | Buy |
| MA 50 | $8.67 | Buy | $9.39 | Buy |
| MA 100 | $6.76 | Buy | $7.47 | Buy |
| MA 200 | $4.65 | Buy | $5.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 40.38 | Neutral |
| Williams %R (14) | -38.87 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 40.68 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 61.13 | Neutral |
| TRIX (15) | 2.52 | Buy |
| Awesome (5,34) | 3.54 | Buy |
| Ultimate (7,14,28) | 46.45 | Neutral |
| Momentum (10) | 2.23 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 13.17 | Buy |
| ADX (14) | 29.31 | Buy |
| ATR (14) | 0.75 | Info |
The 30-day range runs from $8.52 to $21.40, illustrating a wide trading band over the last month.
The technical setup shows bullish sentiment, with RSI at 60, and prices above both the SMA50 of $8.15 and the SMA200 of $4.48, signaling improving near-term momentum.
Key support sits at $7.15, while resistance is near $15.45. These levels frame short-term risk and reward as price action tests the mid-range, with a generally constructive tilt in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.46 | $13.51 | $20.09 | 0% | Neutral | |
| $10.89 | $15.01 | $22.38 | +11% | Neutral | |
| $12.93 | $18.95 | $30.09 | +40% | Bullish | |
| $16.81 | $25.94 | $43.25 | +92% | Bullish | |
| $20.32 | $32.87 | $57.05 | +143% | Bullish | |
| $19.56 | $33.07 | $59.41 | +145% | Bullish | |
| $17.37 | $30.64 | $56.76 | +127% | Bullish | |
| $19.86 | $36.47 | $69.44 | +170% | Bullish | |
| $18.39 | $35.13 | $68.59 | +160% | Bullish | |
| $20.12 | $39.95 | $79.81 | +196% | Bullish | |
| $23.97 | $53.27 | $116.95 | +294% | Bullish | |
| $75.81 | $168.47 | $387.49 | +11.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.46 | $13.51 | $15.97 | +0.00% |
| August 2026 | $10.75 | $13.03 | $16.45 | -3.57% |
| September 2026 | $11.66 | $14.33 | $18.47 | +10.03% |
| October 2026 | $12.01 | $14.94 | $19.59 | +4.21% |
| November 2026 | $11.51 | $14.47 | $19.25 | -3.13% |
| December 2026 | $11.75 | $14.91 | $20.09 | +3.02% |
Click any year to see its month-by-month SLS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
SELLAS Life Sciences Group, Inc.'s 2026 outlook centres on $13.51, within a $3.46 to $20.09 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SLS could reach as high as $22.38, with a base case around $15.01 and support toward $10.89 — roughly +11% from $13.51. Price action looks broadly range-bound.
Expect SLS to range from $12.93 to $30.09 through 2028. The $18.95 average target implies a +40% move from current prices. That is up +26% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The SLS price prediction for 2029 points to an average of $25.94 (low $16.81, high $43.25) — a potential gain of +92% on today's $13.51. Momentum favours further upside here.
In 2030, SLS is projected to trade between $20.32 and $57.05, averaging $32.87 — a potential gain of +143% from today's $13.51. That is up +27% on the projected 2029 average. Buyers look set to stay in control over this stretch.
SELLAS Life Sciences Group, Inc.'s 2031 outlook centres on $33.07, within a $19.56 to $59.41 range. That is up +1% on the projected 2030 average. That marks a +145% change versus current levels. Momentum favours further upside here.
By 2032, SLS could reach as high as $56.76, with a base case around $30.64 and support toward $17.37 — roughly +127% from $13.51. Buyers look set to stay in control over this stretch.
Expect SLS to range from $19.86 to $69.44 through 2033. The $36.47 average target implies a +170% move from current prices. That is up +19% on the projected 2032 average. Momentum favours further upside here.
The SLS price prediction for 2034 points to an average of $35.13 (low $18.39, high $68.59) — a potential gain of +160% on today's $13.51. Buyers look set to stay in control over this stretch.
In 2035, SLS is projected to trade between $20.12 and $79.81, averaging $39.95 — a potential gain of +196% from today's $13.51. That is up +14% on the projected 2034 average. Momentum favours further upside here.
SELLAS Life Sciences Group, Inc.'s 2040 outlook centres on $53.27, within a $23.97 to $116.95 range. That is up +33% on the projected 2035 average. That marks a +294% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SLS could reach as high as $387.49, with a base case around $168.47 and support toward $75.81 — roughly +11.5x from $13.51. Momentum favours further upside here.
Investing $1,000 in SLS today (≈ 74.019245 SLS) could be worth
$12,470.21
+$11,470.21 (+1147%) by 2050 · US Dollar
Based on the average projected SLS price of $168.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLSwould be worth at today's price.
$1,000 invested in SLS on Jul 10, 2025 (≈ 526.315796 SLS) would be worth
$7,110.53
+$6,110.53 (+611.1%) today · 7.11× · US Dollar
Based on a SLS entry price of $1.9 vs. today's $13.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.98 | $901.87 | -9.8% |
| 1 month ago | $7.15 | $1,889.51 | +89.0% |
| 3 months ago | $4.76 | $2,838.24 | +183.8% |
| 6 months ago | $4.11 | $3,287.1 | +228.7% |
| 1 year ago | $1.9 | $7,110.53 | +611.1% |
| All time (5.0y) ago | $8.87 | $1,523.11 | +52.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLS forecast.
Our base-case forecast reaches $27.00 around 2030.
Implied market cap at $27.00: $5.31B
The long-range forecast outlines a progressively higher price trajectory across years. The 2026 average is $13.50 with a 0 ROI, advancing to a 2027 average of $14.95 (ROI 10.7%) and a 2028 average of $18.91 (ROI 40.1%). The 2029 average is $26.20 (ROI 94%), and the 2030 average rises to $32.75 (ROI 142.6%), with continuing gains through 2031 ($32.89 avg, ROI 143.6%) and 2032 ($30.88 avg, ROI 128.8%).
The 2033 average is $36.38 (ROI 169.5%), 2034 is $34.97 (ROI 159.1%), and 2035 is $40.20 (ROI 197.8%).
Beyond the mid-decade, the forecast extends to 2040 with an average of $53.11 (ROI 293.4%), and to 2050 with an average of $169.30 (ROI 1154.1%), all bearing bullish sentiment. These figures imply substantial upside if the forecast path materializes, though they remain estimates and are not guarantees. Uncertainty and variability are inherent in long-horizon projections.
Tap a question to reveal the answer.
The 2030 average price is $32.75, with a minimum of $20.24 and a maximum of $56.85; ROI 142.6; sentiment BULLISH.
Forecasts show rising average prices through 2050, with the 2050 average at $169.30 and ROI at 1154.1%; sentiment BULLISH in the long horizon, though these figures are estimates.
Yes. The 2027 maximum is $22.29.
The current technical sentiment is BULLISH.
The forecast shows a path of rising averages, with 2040 average at $53.11 (ROI 293.4%) and 2050 average at $169.30 (ROI 1154.1%), indicating substantial upside potential over the long term, contingent on market and clinical development outcomes.
SELLAS Life Sciences Group, Inc. Community Discussion
0Share your SELLAS Life Sciences Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.